Recursion Pharmaceuticals (RXRX) Free Cash Flow (2020 - 2026)

Recursion Pharmaceuticals' Free Cash Flow history runs 7 years deep, the most recent figure standing at -$81.4 million for Q1 2026.

• Quarterly Free Cash Flow rose 39.19% year-over-year to -$81.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$319.4 million (up 19.69% YoY) and the FY2025 annual result came in at -$371.8 million, changed 0.28% from the prior year.
• Free Cash Flow was -$81.4 million for Q1 2026 at Recursion Pharmaceuticals, down from -$40.8 million in the prior quarter.
• Across five years, Free Cash Flow topped out at $73.0 million in Q1 2022 and bottomed at -$133.8 million in Q1 2025.
• A 5-year average of -$71.2 million and a median of -$74.8 million in 2025 frame the typical range for Free Cash Flow.
• Annual changes were most pronounced in 2022 — Free Cash Flow soared 332.19% — and 2023, when it tumbled 207.45%.
• Recursion Pharmaceuticals' Free Cash Flow stood at -$42.2 million in 2022, then plunged by 103.65% to -$86.0 million in 2023, then sank by 35.68% to -$116.7 million in 2024, then jumped by 65.01% to -$40.8 million in 2025, then plunged by 99.17% to -$81.4 million in 2026.
• Business Quant data shows RXRX's Free Cash Flow at -$81.4 million in Q1 2026, -$40.8 million in Q4 2025, and -$122.3 million in Q3 2025.